权益市场真是充满了情_老虎社区_美港股上老虎 - 老虎社区

权益市场真是充满了情绪，有了稍微靠谱点的治病特效药，就不需要预防的疫苗了吗？

港股医药板块跌势扩大，抗疫概念股大跌

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

虎头纹
2021-10-04
虎头纹
你自己觉着呢？

发表看法

1

2

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":867774816,"tweetId":"867774816","gmtCreate":1633319816707,"gmtModify":1633322038651,"author":{"id":3442341479209997,"idStr":"3442341479209997","authorId":3442341479209997,"authorIdStr":"3442341479209997","name":"bgo2002","avatar":"https://static.tigerbbs.com/5bb15342ec7e704d9c6051cf67b1d9c3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>权益市场真是充满了情绪，有了稍微靠谱点的治病特效药，就不需要预防的疫苗了吗？</p></body></html>","htmlText":"<html><head></head><body><p>权益市场真是充满了情绪，有了稍微靠谱点的治病特效药，就不需要预防的疫苗了吗？</p></body></html>","text":"权益市场真是充满了情绪，有了稍微靠谱点的治病特效药，就不需要预防的疫苗了吗？","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/867774816","repostId":1113920936,"repostType":4,"repost":{"id":"1113920936","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1633312050,"share":"https://www.laohu8.com/m/news/1113920936?lang=&edition=full","pubTime":"2021-10-04 09:47","market":"sh","language":"zh","title":"港股医药板块跌势扩大，抗疫概念股大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1113920936","media":"老虎资讯综合","summary":"10月4日讯，港股医药板块跌势扩大，恒生医疗保健业指数下挫逾4%，抗疫概念股大跌，其中开拓药业大跌22%，复星医药跌近20%，康希诺生物跌逾11%。默沙东新冠口服药数据高度有效，美股疫苗公司CureV","content":"<p>10月4日讯，港股医药板块跌势扩大，恒生医疗保健业指数下挫逾4%，抗疫概念股大跌，其中开拓药业大跌22%，<a href=\"https://laohu8.com/S/600196\">复星医药</a>跌近20%，<a href=\"https://laohu8.com/S/688185\">康希诺</a>生物跌逾11%。<a href=\"https://laohu8.com/S/MRK\">默沙东</a>新冠口服药数据高度有效，美股疫苗公司CureVac上周五收跌逾14.7%，诺瓦瓦克斯跌12.4%，莫德纳跌约11.4%。</p>\n<p>10月1日，美国<a href=\"https://laohu8.com/S/MRK\">默沙东</a>公布实验性新冠口服药物莫奈拉韦（molnupiravir）三期临床试验的“期中考”成绩。数据显示，如患者在感染早期服用莫奈拉韦，可将患者的住院或死亡风险降低50%。基于此，默沙东已提前终止该三期临床试验，希望通过“紧急授权”（EUA）这一绿色通道，提前上市。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股医药板块跌势扩大，抗疫概念股大跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股医药板块跌势扩大，抗疫概念股大跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-10-04 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>10月4日讯，港股医药板块跌势扩大，恒生医疗保健业指数下挫逾4%，抗疫概念股大跌，其中开拓药业大跌22%，<a href=\"https://laohu8.com/S/600196\">复星医药</a>跌近20%，<a href=\"https://laohu8.com/S/688185\">康希诺</a>生物跌逾11%。<a href=\"https://laohu8.com/S/MRK\">默沙东</a>新冠口服药数据高度有效，美股疫苗公司CureVac上周五收跌逾14.7%，诺瓦瓦克斯跌12.4%，莫德纳跌约11.4%。</p>\n<p>10月1日，美国<a href=\"https://laohu8.com/S/MRK\">默沙东</a>公布实验性新冠口服药物莫奈拉韦（molnupiravir）三期临床试验的“期中考”成绩。数据显示，如患者在感染早期服用莫奈拉韦，可将患者的住院或死亡风险降低50%。基于此，默沙东已提前终止该三期临床试验，希望通过“紧急授权”（EUA）这一绿色通道，提前上市。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/58c571cf0b4357240a7b67c1db539b4a","relate_stocks":{"159938":"医药","09939":"开拓药业-B"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113920936","content_text":"10月4日讯，港股医药板块跌势扩大，恒生医疗保健业指数下挫逾4%，抗疫概念股大跌，其中开拓药业大跌22%，复星医药跌近20%，康希诺生物跌逾11%。默沙东新冠口服药数据高度有效，美股疫苗公司CureVac上周五收跌逾14.7%，诺瓦瓦克斯跌12.4%，莫德纳跌约11.4%。\n10月1日，美国默沙东公布实验性新冠口服药物莫奈拉韦（molnupiravir）三期临床试验的“期中考”成绩。数据显示，如患者在感染早期服用莫奈拉韦，可将患者的住院或死亡风险降低50%。基于此，默沙东已提前终止该三期临床试验，希望通过“紧急授权”（EUA）这一绿色通道，提前上市。","news_type":1},"isVote":1,"tweetType":1,"viewCount":649,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":73,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":6091190,"commentId":"6091190","gmtCreate":1633361520738,"gmtModify":1633361520738,"authorId":3546388162494555,"author":{"id":3546388162494555,"idStr":"3546388162494555","authorId":3546388162494555,"name":"虎头纹","avatar":"https://static.tigerbbs.com/8934413c88fa3561ac1ad796c526e589","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":867774816,"objectIdStr":"867774816","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"你自己觉着呢？","text":"你自己觉着呢？","html":"你自己觉着呢？","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/867774816"}